Mirum's Brelovitug Hits Primary Endpoint in Phase 3 HDV Trial
Event summary
- Mirum's brelovitug met primary endpoint in Phase 3 AZURE-1 study for chronic hepatitis delta virus (HDV), with 56% of patients in the 300 mg QW arm achieving virologic response and ALT normalization at Week 24.
- 48-week data from Phase 2b portion showed deepening viral suppression and increased ALT normalization rates.
- Mirum plans to submit a Biologics License Application (BLA) to the FDA in H1 2027, with potential commercial launch in Q4 2027.
- Topline results from the Phase 3 AZURE-4 study are expected in Q4 2026.
The big picture
Mirum's positive Phase 3 data for brelovitug represents a significant step forward in the treatment of chronic HDV, a condition with no approved therapies in the U.S. The results underscore the potential of monoclonal antibodies in addressing rare liver diseases and highlight Mirum's strategic focus on developing therapies for overlooked conditions. The upcoming AZURE-4 data and regulatory submission will be critical in determining the commercial viability of brelovitug.
What we're watching
- Regulatory Pathway
- Whether the AZURE-4 results will support the BLA submission and expedite the approval process.
- Market Potential
- The pace at which Mirum can commercialize brelovitug if approved, given the lack of current treatments for HDV.
- Competitive Landscape
- How Mirum's progress with brelovitug positions it against potential competitors in the HDV treatment space.